AFM
PBLA

Anson Funds Management’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Anson Funds Management’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-272
Closed -$72.1K – 223
2023
Q1 		$72.1K Buy
+272
New +$264K 0.01% 175

Other funds holding PBLA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Anson Funds Management's PBLA Position: Q2 2023 in Review

Anson Funds Management sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q2 2023, closing a stake of 272 shares — an estimated $72.1K sold.

Anson Funds Management first reported a position in PBLA in Q1 2023 and held it in 1 quarter. The position peaked at $72.1K in Q1 2023. 6 funds tracked by Wall St. Rank hold PBLA as of Q2 2023.

  • Anson Funds Management reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Anson Funds Management sold 272 Panbela Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $72.1K.
  • Anson Funds Management first reported a position in Panbela Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Anson Funds Management's Panbela Therapeutics, Inc. Common Stock position peaked at $72.1K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Anson Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.